Cancer
|
OPPORTUNITY NUMBER |
OPPORTUNITY TITLE |
AGENCY NAME |
POSTED DATE |
CLOSE DATE |
| PAR-24-082 | Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) | HHS-NIH11 | 12/12/2023 | 03/13/2024 |
| RFA-CA-24-009 | Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | HHS-NIH11 | 11/29/2023 | 10/01/2024 |
| RFA-CA-24-011 | Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | HHS-NIH11 | 11/28/2023 | 10/01/2024 |
| RFA-CA-24-010 | Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | HHS-NIH11 | 11/28/2023 | 10/01/2024 |
| RFA-CA-24-008 | Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | HHS-NIH11 | 11/28/2023 | 10/01/2024 |
| RFA-CA-24-014 | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) | HHS-NIH11 | 11/28/2023 | 10/01/2024 |
| RFA-CA-24-015 | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional) | HHS-NIH11 | 11/28/2023 | 10/01/2024 |
| RFA-CA-24-012 | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) | HHS-NIH11 | 11/28/2023 | 10/01/2024 |
| PAR-23-286 | NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) | HHS-NIH11 | 11/08/2023 | 10/14/2026 |
| PAR-23-288 | NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required) | HHS-NIH11 | 11/08/2023 | 10/14/2026 |
| PAR-23-287 | NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) | HHS-NIH11 | 11/08/2023 | 10/14/2026 |
| PAR-24-039 | Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 11/01/2023 | 11/17/2026 |
| PAR-23-276 | Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 09/29/2023 | 01/07/2027 |
| PAR-23-284 | Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) | HHS-NIH11 | 09/22/2023 | 09/25/2026 |
| PAR-23-277 | Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 09/21/2023 | 01/07/2027 |
| PAR-23-278 | Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 09/21/2023 | 01/07/2027 |
| PAR-23-292 | Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) | HHS-NIH11 | 09/07/2023 | 01/07/2027 |
| PAR-23-280 | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 08/24/2023 | 01/07/2027 |
| PAR-23-279 | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | HHS-NIH11 | 08/23/2023 | 01/07/2027 |
| RFA-AG-24-046 | Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 08/23/2023 | 02/07/2024 |
| RFA-CA-23-042 | The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) | HHS-NIH11 | 08/21/2023 | 11/19/2024 |
| PAR-23-281 | Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 08/18/2023 | 09/07/2026 |
| PAR-23-244 | Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | HHS-NIH11 | 08/15/2023 | 01/07/2027 |
| PAR-23-264 | Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 08/10/2023 | 09/07/2026 |
| PAR-23-273 | Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) | HHS-NIH11 | 08/10/2023 | 05/07/2026 |
| PAR-23-243 | NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) | HHS-NIH11 | 08/09/2023 | 11/03/2025 |
| PAR-23-242 | NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) | HHS-NIH11 | 08/09/2023 | 11/03/2025 |
| PAR-23-259 | Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | HHS-NIH11 | 08/08/2023 | 01/07/2027 |
| PAR-23-254 | Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 08/01/2023 | 09/07/2026 |
| PAR-23-255 | Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | HHS-NIH11 | 08/01/2023 | 09/07/2026 |
| PAR-23-246 | Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) | HHS-NIH11 | 07/20/2023 | 05/04/2026 |
| PAR-23-170 | Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) | HHS-NIH11 | 04/19/2023 | 01/07/2027 |
| PAR-23-155 | Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) | HHS-NIH11 | 04/12/2023 | 05/07/2026 |
| PAR-23-153 | Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) | HHS-NIH11 | 03/30/2023 | 05/07/2026 |
| PAR-23-152 | Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) | HHS-NIH11 | 03/30/2023 | 05/07/2026 |
| PAR-23-075 | Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) | HHS-NIH11 | 12/23/2022 | 01/07/2026 |
| PAR-23-059 | National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional) | HHS-NIH11 | 12/14/2022 | 05/07/2026 |
| PAR-23-056 | Co-infection and Cancer (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 12/14/2022 | 11/16/2025 |
| PAR-23-055 | Co-infection and Cancer (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 12/14/2022 | 11/05/2025 |
| PAR-23-058 | NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | HHS-NIH11 | 12/05/2022 | 01/07/2026 |
| RFA-DK-22-027 | Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) | HHS-NIH11 | 11/28/2022 | 10/19/2023 |
| RFA-CA-22-050 | NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional) | HHS-NIH11 | 09/01/2022 | 02/06/2024 |
| RFA-CA-22-045 | NCI Outstanding Investigator Award (R35 Clinical Trial Optional) | HHS-NIH11 | 07/26/2022 | 11/07/2024 |
| PAR-22-218 | Biology of Bladder Cancer (R01 Clinical Trial Optional) | HHS-NIH11 | 07/26/2022 | 09/07/2025 |
| PAR-22-219 | Biology of Bladder Cancer (R21 Clinical Trial Optional) | HHS-NIH11 | 07/26/2022 | 09/07/2025 |
| PAR-22-216 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | HHS-NIH11 | 07/14/2022 | 07/01/2025 |
| PAR-22-173 | Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | HHS-NIH11 | 06/23/2022 | 09/07/2025 |
| PAR-22-199 | Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional) | HHS-NIH11 | 06/14/2022 | 09/07/2025 |
| PAR-22-165 | Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) | HHS-NIH11 | 06/13/2022 | 09/07/2025 |
| PAR-22-164 | Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) | HHS-NIH11 | 06/13/2022 | 09/07/2025 |
| PAR-22-131 | Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional) | HHS-NIH11 | 04/12/2022 | 09/07/2025 |
| PAR-22-136 | Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) | HHS-NIH11 | 04/11/2022 | 06/17/2024 |
| PAR-22-140 | Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 03/18/2022 | 05/07/2025 |
| PAR-22-139 | Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 03/18/2022 | 05/07/2025 |
| PAR-22-114 | Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) | HHS-NIH11 | 02/25/2022 | 01/23/2025 |
| PAR-22-086 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 02/18/2022 | 05/07/2025 |
| PAR-22-085 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 02/18/2022 | 05/07/2025 |
| PAR-22-084 | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 01/21/2022 | 05/07/2025 |
| PAR-22-099 | Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) | HHS-NIH11 | 01/21/2022 | 05/07/2025 |
| PAR-22-083 | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 01/21/2022 | 05/07/2025 |
| PAR-22-071 | Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 11/23/2021 | 11/17/2024 |
| PAR-22-062 | Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 11/03/2021 | 01/07/2025 |
| PAR-22-061 | Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 11/03/2021 | 01/07/2025 |
| PAR-21-329 | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | HHS-NIH11 | 09/22/2021 | 11/05/2024 |
| PAR-21-300 | NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed) | HHS-NIH11 | 09/10/2021 | 09/07/2024 |
| PAR-21-302 | NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required) | HHS-NIH11 | 09/10/2021 | 09/07/2024 |
| PAR-21-299 | NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required) | HHS-NIH11 | 09/10/2021 | 09/07/2024 |
| PAR-21-296 | NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required) | HHS-NIH11 | 08/31/2021 | 11/12/2024 |
| PAR-21-295 | NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) | HHS-NIH11 | 08/31/2021 | 11/12/2024 |
| PAR-21-278 | Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 08/26/2021 | 09/07/2024 |
| PAR-21-279 | Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 08/26/2021 | 09/07/2024 |
| PAR-21-294 | Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 07/22/2021 | 09/07/2024 |
| PAR-21-290 | Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) | HHS-NIH11 | 07/22/2021 | 09/07/2024 |
| PAR-21-138 | Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | HHS-NIH11 | 06/03/2021 | 12/01/2024 |
| PAR-21-138 | Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | HHS-NIH11 | 06/03/2021 | 12/01/2024 |
| PAR-21-128 | The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed) | HHS-NIH11 | 03/15/2021 | 03/14/2024 |
| PAR-21-318 | The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required) | HHS-NIH11 | 03/15/2021 | 03/14/2024 |
| PAR-21-111 | The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required) | HHS-NIH11 | 03/15/2021 | 03/14/2024 |
| PAR-21-190 | Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | HHS-NIH11 | 03/12/2021 | 03/07/2024 |
| PAR-21-065 | Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 11/17/2020 | 01/07/2024 |
| PAR-21-066 | Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 11/17/2020 | 01/07/2024 |
| PAR-21-067 | Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 11/17/2020 | 01/07/2024 |
| PAR-21-033 | National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | HHS-NIH11 | 11/12/2020 | 01/07/2024 |
| PAR-21-035 | Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | HHS-NIH11 | 11/10/2020 | 01/07/2024 |
| PAR-20-305 | Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required) | HHS-NIH11 | 09/28/2020 | 01/07/2024 |